BR112023026514A2 - Método para preparar um composto [18f] radiomarcado - Google Patents

Método para preparar um composto [18f] radiomarcado

Info

Publication number
BR112023026514A2
BR112023026514A2 BR112023026514A BR112023026514A BR112023026514A2 BR 112023026514 A2 BR112023026514 A2 BR 112023026514A2 BR 112023026514 A BR112023026514 A BR 112023026514A BR 112023026514 A BR112023026514 A BR 112023026514A BR 112023026514 A2 BR112023026514 A2 BR 112023026514A2
Authority
BR
Brazil
Prior art keywords
preparing
radio
labelled compound
water content
radiolabeled compound
Prior art date
Application number
BR112023026514A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Clarke
Alexander Jackson
Graeme Mcrobbie
Ahmed Khan Imtiaz
Jonathan Shales
Julian Grigg
Kristine Wikene
Torgrim Engell
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of BR112023026514A2 publication Critical patent/BR112023026514A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
BR112023026514A 2021-06-16 2022-06-16 Método para preparar um composto [18f] radiomarcado BR112023026514A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108605.3A GB202108605D0 (en) 2021-06-16 2021-06-16 Effect of water content
PCT/EP2022/066483 WO2022263594A1 (en) 2021-06-16 2022-06-16 Method for preparing an [18f] radiolabelled compound with low water content during labelling step

Publications (1)

Publication Number Publication Date
BR112023026514A2 true BR112023026514A2 (pt) 2024-03-05

Family

ID=76954450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026514A BR112023026514A2 (pt) 2021-06-16 2022-06-16 Método para preparar um composto [18f] radiomarcado

Country Status (12)

Country Link
US (2) US20240366808A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355715A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522770A (cg-RX-API-DMAC7.html)
KR (1) KR20240021888A (cg-RX-API-DMAC7.html)
CN (1) CN117500773A (cg-RX-API-DMAC7.html)
AU (1) AU2022294052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026514A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223802A1 (cg-RX-API-DMAC7.html)
GB (1) GB202108605D0 (cg-RX-API-DMAC7.html)
IL (1) IL308917A (cg-RX-API-DMAC7.html)
MX (1) MX2023015076A (cg-RX-API-DMAC7.html)
WO (1) WO2022263594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520527D0 (en) 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
AU2011213568B2 (en) 2010-02-08 2016-05-12 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
DK2880005T3 (en) * 2012-07-30 2016-07-18 Univ Denmark Tech Dtu RADIO FLUOR RING PROCEDURE
WO2016086036A2 (en) * 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US10716869B2 (en) * 2016-02-29 2020-07-21 Oncodesign Sa Radiolabeled macrocyclic EGFR inhibitor
ES2907130T3 (es) * 2017-09-26 2022-04-22 Inst Nat Sante Rech Med Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction

Also Published As

Publication number Publication date
AU2022294052A1 (en) 2023-12-14
EP4355715A1 (en) 2024-04-24
MX2023015076A (es) 2024-01-18
GB202108605D0 (en) 2021-07-28
KR20240021888A (ko) 2024-02-19
IL308917A (en) 2024-01-01
US20250312494A1 (en) 2025-10-09
CA3223802A1 (en) 2022-12-22
WO2022263594A1 (en) 2022-12-22
JP2024522770A (ja) 2024-06-21
US20240366808A1 (en) 2024-11-07
CN117500773A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
BR112013033837A2 (pt) retardante de cimento e processo de utilização do mesmo
BR112014009009A2 (pt) método melhorado de tratamento de água com dióxido de cloro
BRPI0822183A2 (pt) Processo para redução do teor de lementos tais como boro em halogenossilanos, bem como instalacões para realização do processo
AR115297A1 (es) Método para concentración y purificación de eluato de salmuera para la producción de un compuesto de litio purificado
BR112014017585A8 (pt) processo para produção de hexametileno diamina a partir de materiais contendo carboidrato e intermediários para os mesmos
EA202092139A2 (ru) Способы производства сульфата калия и хлорида натрия из сточных вод
EP2749565A4 (en) GLYCOSIDE COMPOUND, METHOD FOR THE PRODUCTION OF THIOETHERS, ETHER, METHOD FOR THE PRODUCTION OF, ETHER, METHOD FOR THE PRODUCTION OF A GLYCOSIDE COMPOUND, PROCESS FOR THE PREPARATION OF A NUCLEIC ACID
MY184911A (en) Method for producing aei zeolite
BR112014014062A2 (pt) produção de 1,3-dienos por conversão enzimática de 3- hidroxialc-4-enoatos e/ou 3-fosfonoxialc-4-enoatos
BR112019002417A2 (pt) cristalização de glicosídeos de esteviol
BR112023024667A2 (pt) Processo para tratamento de um sulfato de sódio que contém corrente de processo de resíduos de uma instalação de produção de bateria, uma instalação de reciclagem de bateria ou uma usina de produção de aço
BR112012019011A2 (pt) "processo para fazer zeólito de titânio- mww".
BR112014018044A8 (pt) Processo para preparação de sílicas precipitadas
TN2015000372A1 (en) A method for concentrating rare-earth metals in phosphogypsum
BR112014014648A8 (pt) catalisador para a síntese de mercaptanos de alquila e processo para a sua produção
NZ597315A (en) Environmentally-friendly cementitious articles, formulations, methods of making and uses
BR112018070701A2 (pt) processo para destilação de uma mistura de aldeídos.
BR112015021526A2 (pt) produção de ácido fosfórico por um processo de cristalização em dois estágios
CN104557517B (zh) 一种废柠檬酸钠母液综合处理工艺
BR112015013021A2 (pt) método para a produção de sal mineral e produtos com sal mineral
AR068520A1 (es) Proceso para la produccion de sulfato de sodio e hidroxido de magnesio
BR112012008030A2 (pt) processo para a purificação de uma corrente aquosa proviniente da reação fischer-tropsch
FR3062851B1 (fr) Procede de preparation monotope de composes organo-iodes
BR112022015754A2 (pt) Processo para a síntese de s-beflubutamid a partir do ácido (r)-2-aminobutanoico
BR112015014801A2 (pt) processo de produção de oligossacarídeos, a partir de biomassa lignocelulósica

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]